Agenus to Report Fourth Quarter and Year End 2013 Financial Results on March 5, 2014; Conference Call to Follow

  Agenus to Report Fourth Quarter and Year End 2013 Financial Results on March
  5, 2014; Conference Call to Follow

Business Wire

LEXINGTON, Mass. -- February 27, 2014

Agenus Inc. (NASDAQ: AGEN) will release its fourth quarter and year end 2013
financial results before the market opens on March 5, 2014.

Agenus executives will host a conference call at 11:00 a.m. Eastern Time that
same day. To access the live call, dial 647-426-1845. The call will also be
webcast and will be accessible from the company’s website at
www.agenusbio.com/webcast/. A replay will be available approximately two hours
after the call through midnight Eastern Time on May 5, 2014. The replay number
is 416-915-1035, and the access code is 498676. The replay will also be
available on the company’s website approximately two hours after the live
call.

About Agenus

Agenus is a biopharmaceutical company focused on immuno-oncology with a
portfolio of checkpoint modulators and anti-cancer vaccines. The company’s
three platforms include checkpoint modulators, heat shock protein based
vaccines, and adjuvants. The company’s proprietary discovery engine Retrocyte
Display^® generates high quality therapeutic antibody drug candidates quickly
using a high-throughput approach incorporating full-length IgG format human
antibody libraries expressed in mammalian B-lineage cells. A portfolio of
checkpoint modulator programs is advancing in preclinical development, several
heat shock protein vaccines are in Phase 2 studies, and the QS-21 Stimulon^®
adjuvant platform is extensively partnered with GlaxoSmithKline and Janssen
and includes several candidates in late-stage trials. Among Agenus and its
partners, 23 programs are in clinical development. For more information,
please visit www.agenusbio.com, or connect with the company on Facebook,
LinkedIn, Twitter and Google+.

Contact:

Media and Investor Contact:
Agenus Inc.
Jonae R. Barnes, 617-818-2985
Vice President
Investor Relations and Corporate Communications
jonae.barnes@agenusbio.com
 
Press spacebar to pause and continue. Press esc to stop.